Extensive data presented at the congress on the apoCIII antisense oligonucleotide, olezarsen, recently approved in the USA for adults with familial chylomicronaemia syndrome (FCS), supported its positive effects on lipoprotein profiles and potential benefits for resource utilisation.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
